

BROADSPECTRUM 2-AMINO-BENZOTHAZOLE SULFONAMIDE HIV
PROTEASE INHIBITORS

5

$$\begin{array}{c} \text{R}^1-\text{L}-\text{C}(=\text{O})-\text{N}(\text{R}^2)-\text{CH}(\text{R}^3)-\text{CH}(\text{OH})-\text{CH}_2-\text{N}(\text{R}^4)-\text{SO}_2-\text{C}_6\text{H}_4-\text{N}(\text{R}^5)=\text{N}(\text{R}^6) \end{array} \quad (\text{I})$$

wherein R₁ is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C₁₋₆alkyl, hydroxy, amino, halogen, aminoC₁₋₄alkyl and mono- or di(C₁₋₄alkyl)amino; R₂ is hydrogen or C₁₋₆alkyl; L is a direct bond, -O-, C₁₋₆alkanediyl-O- or -O-C₁₋₆alkanediyl; R₃ is phenylC₁₋₄alkyl; R₄ is C₁₋₆alkyl; R₅ is hydrogen or C₁₋₆alkyl; R₆ is hydrogen or C₁₋₆alkyl; in the manufacture of a medicament useful for inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease. It also relates to novel compounds of formula (I).